Jarosław Sobiś1, Monika Rykaczewska-Czerwińska2, Elżbieta Świętochowska3, Piotr Gorczyca4. 1. Medical University of Silesia, School of Medicine with the Division of Dentistry, Chair and Department of Psychiatry, Tarnowskie Góry, Poland. Electronic address: jaroslaw.sobis@poczta.onet.pl. 2. Medical University of Silesia, School of Public Health, Chair of Toxicology and Drug Addiction, Department of Toxicology and Health Protection, Katowice, Poland. 3. Medical University of Silesia, School of Medicine with the Division of Dentistry, Chair of Biochemistry, Department of Clinical Biochemistry, Zabrze, Poland. 4. Medical University of Silesia, School of Medicine with the Division of Dentistry, Chair and Department of Psychiatry, Tarnowskie Góry, Poland.
Abstract
BACKGROUND: Weight gain and metabolic abnormalities occur in chronic schizophrenia patients treated with atypical antipsychotics. The purpose of the study was to evaluate changes in serum levels of C-reactive protein (CRP), insulin and cytokines (IL-6, TNF-α, IL-1β, IFN-γ, sTNF-R1, IL-12, IL-23, IL-1Ra, TGF-β1, IL-4, and IL-10) after switching to aripiprazole. METHODS: Cytokine, hsCRP and insulin measurements were performed in patients (n=17) on day 0 and day 28 of the study using standard ELISA assays. The psychopathological status was assessed using PANSS. WC and BMI were measured and calculated, respectively. RESULTS: We observed high clinical efficacy in aripiprazole linked to a 2.7% weight loss. There were statistically significant reductions in PANSS scores and body parameters (p<0.001). After 28 days we detected a significant reduction in hsCRP (p<0.001), insulin (p<0.001), IL-1β, IL-6, TNF-α, sTNF-R1, IL-12, IL-23, IL-1Ra, TGF-β1, IL-4 (p<0.001), IFN-γ (p<0.05) and a significant elevation of IL-10 (p<0.001). There was a significant negative correlation between IL-10 levels and PANSS positive, negative and total scores after the study (p=0.022, p=0.003, p=0.008, respectively). CONCLUSIONS: Aripiprazole limits inflammatory processes by enhancing anti-inflammatory signaling. Aripiprazole also reduces the risk of metabolic abnormalities.
BACKGROUND:Weight gain and metabolic abnormalities occur in chronic schizophreniapatients treated with atypical antipsychotics. The purpose of the study was to evaluate changes in serum levels of C-reactive protein (CRP), insulin and cytokines (IL-6, TNF-α, IL-1β, IFN-γ, sTNF-R1, IL-12, IL-23, IL-1Ra, TGF-β1, IL-4, and IL-10) after switching to aripiprazole. METHODS: Cytokine, hsCRP and insulin measurements were performed in patients (n=17) on day 0 and day 28 of the study using standard ELISA assays. The psychopathological status was assessed using PANSS. WC and BMI were measured and calculated, respectively. RESULTS: We observed high clinical efficacy in aripiprazole linked to a 2.7% weight loss. There were statistically significant reductions in PANSS scores and body parameters (p<0.001). After 28 days we detected a significant reduction in hsCRP (p<0.001), insulin (p<0.001), IL-1β, IL-6, TNF-α, sTNF-R1, IL-12, IL-23, IL-1Ra, TGF-β1, IL-4 (p<0.001), IFN-γ (p<0.05) and a significant elevation of IL-10 (p<0.001). There was a significant negative correlation between IL-10 levels and PANSS positive, negative and total scores after the study (p=0.022, p=0.003, p=0.008, respectively). CONCLUSIONS:Aripiprazole limits inflammatory processes by enhancing anti-inflammatory signaling. Aripiprazole also reduces the risk of metabolic abnormalities.
Authors: Tyler A Lesh; Milo Careaga; Destanie R Rose; A Kimberley McAllister; Judy Van de Water; Cameron S Carter; Paul Ashwood Journal: J Neuroinflammation Date: 2018-05-26 Impact factor: 8.322
Authors: Anastasiia S Boiko; Irina A Mednova; Elena G Kornetova; Valeria I Gerasimova; Alexander N Kornetov; Anton J M Loonen; Nikolay A Bokhan; Svetlana A Ivanova Journal: Pharmaceuticals (Basel) Date: 2021-05-09